Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

BACKGROUND: The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Respir Res
Hlavní autoři: Liu, Mark C., Chipps, Bradley, Munoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Smith, Steven G., Price, Robert G., Galkin, Dmitry V., Azmi, Jay, Mouneimne, Dalal, Albers, Frank C., Chapman, Kenneth R.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111733/
https://ncbi.nlm.nih.gov/pubmed/33971856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01733-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky